# Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)

> **NCT03091933** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ciusss de L'Est de l'Île de Montréal** · enrollment: 20 (estimated)

## Conditions studied

- Hematologic Cancer
- Relapse Leukemia
- Relapsed Adult ALL
- Relapsed Adult AML
- Relapsed CLL
- Relapsed Non Hodgkin Lymphoma
- Relapsed Hodgkin's Lymphoma
- Relapsed Myelodysplastic Syndromes
- Relapsed Multiple Myeloma

## Interventions

- **BIOLOGICAL:** GLIDE

## Key facts

- **NCT ID:** NCT03091933
- **Lead sponsor:** Ciusss de L'Est de l'Île de Montréal
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-06
- **Primary completion:** 2018-03-31
- **Final completion:** 2019-03-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2017-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03091933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03091933, "Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03091933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*